Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics

Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics

This Viewpoint uses the absence of known effective treatment for Ebola virus disease to emphasize the costs of off-label and compassionate drug use during an infectious disease outbreak and the importance of establishing the efficacy and safety of promising drug leads in randomized trials to inform...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2020-05, Vol.323 (19), p.1897-1898
1. Verfasser: Kalil, Andre C
Format: Artikel
Sprache:eng
Schlagworte:
Clinical trials
COVID-19
Drug use
General & Internal Medicine
Infectious diseases
Life Sciences & Biomedicine
Medical treatment
Medicine, General & Internal
Pandemics
Randomization
Science & Technology
Viral diseases
Viruses
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This Viewpoint uses the absence of known effective treatment for Ebola virus disease to emphasize the costs of off-label and compassionate drug use during an infectious disease outbreak and the importance of establishing the efficacy and safety of promising drug leads in randomized trials to inform their clinical use.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2020.4742